[1]吴 迪,房文通.2017-2019年南京地区肠内营养药的应用分析[J].肠外与肠内营养杂志,2021,(04):220-224.[doi:10.16151/j.1007-810x.2021.04.007]
　WU Di,FANG Wen-tong.Analysis on application of enteral nutrition drugs in Nanjing from 2017 to 2019[J].PARENTERAL & ENTERAL NUTRITION,2021,(04):220-224.[doi:10.16151/j.1007-810x.2021.04.007]
点击复制

2017-2019年南京地区肠内营养药的应用分析
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2021年04期
页码:
220-224
栏目:
论著
出版日期:
2021-07-10

文章信息/Info

Title:
Analysis on application of enteral nutrition drugs in Nanjing from 2017 to 2019
作者:
吴 迪; 房文通
南京医科大学第一附属医院药学部，江苏 南京，210029
Author(s):
WU Di;  FANG Wen-tong
Department of Pharmacy, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China
关键词:
肠内营养药 ; 用药分析 ; 用药频度 ; 合理用药
Keywords:
Enteral nutrition drugs;  Drug analysis;  DDDs;  Rational application
分类号:
R459.3
DOI:
10.16151/j.1007-810x.2021.04.007
文献标志码:
A
摘要:
目的：评估南京地区肠内营养(EN)药的临床应用现状及趋势，为临床用药提供参考依据。 方法：对2017 ~ 2019年南京地区 EN药的销售金额、用药频度、限定日费用等进行统计，并结合线性回归分析趋势。 结果：2017 ~ 2019年南京地区 39家医院 EN药的销售金额、用药频度呈逐年增长趋势，2019年销售金额达 14 508.7万元；用药频度排名前 5位分别为安素、百普力、能全素、能全力、瑞代；各药的限定日费用逐年递减，其中安素连续三年最 低；安素、能全素、瑞素、瑞先、能全力等的排序比值>1，性价比高；此外，医院数统计显示百普力、瑞代、康全力、能全力在用医院数均超 20家，市场占有率高。 结论：通用型 EN药物应为治疗首选，短肽型、疾病特异型则各有优势，临床应用应结合 EN药物特点及医保政策，以促进 EN治疗的精准、有效、经济、合理。
Abstract:
Objective: To evaluate the current utilization conditions and future trends of enteral nutrition (EN)drugs in Nanjing，and to provide an important reference for clinical rational use of these drugs. Methods: To analyze the consumption amount, defined daily dose system (DDDs), and defined daily cost (DDC) of EN drugs in Nanjing from 2017 to 2019, and to analyze trends by linear regression. Results: The consumption amount and DDDs of EN drugs increased in 39 hospitals in Nanjing year by year. In 2019, the consumption amount of EN drugs reached 145.087 million yuan. The top five drugs in DDDs were basically concentrated in Ansu, Bipuli, Nengquansu, Nengquanli, and Ruidai. The DDC of EN drugs is decreasing year by year. Among them, Ansu is the lowest for three consecutive years. The B/A of Ansu, Nengquansu, Ruisu, Ruixian, and Nengquanli were above 1, indicating that these drugs were cost-effective. In addition, statistics on the number of hospitals in use show that Bapuli, Ruidai, Kangquanli, and Fully were used in more than 20 hospitals, with a high market share. Conclusion: General EN drugs should be the first choice for treatment,while short peptide EN drugs and disease-specific EN drugs have their own advantages .The clinical application of EN drugs should combine with the characteristics of EN drugs and medical insurance policies to promote an accurate,efficient, economical and rational application of the therapy

参考文献/References:


[1] 蒋朱明, 于 康, 蔡 威 . 临床肠外与肠内营养（第 2版）. 北京:科学技术文献出版社, 2010: 4-6.
[2] 杜 光, 胡俊波 . 临床营养支持与治疗学 . 北京: 科学出版社,2016: 1-5, 173-174.
[3] 陈新谦, 金有豫, 汤 光 . 新编药物学（18版）. 北京: 人民卫生出版社, 2018: 964-971.
[4] 王扬扬 . 肠内营养的临床应用及研究进展 . 医学理论与实践,2015, 28（17）: 2310-2311.
[5] McClave SA, DiBaise JK, Mullin GE, et al. ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient.Am J Gastroenterol, 2016, 111(3):315-334.
[6] 陈莲珍, 费小非, 李 璐, 等 . 肠内营养制剂产品配方评价 . 临床药物治疗杂志, 2019, 17(4):43-46.
[7] 曹相原 . 合理选择肠内营养配方 . 中华重症医学电子杂志,2018,4(1):11-16.
[8] 杨方亮, 江 勇, 姚 捷, 等 . 富含中链脂肪酸和蛋白的肠内营养对恶性梗阻性黄疸手术病人肠屏障功能的影响 . 肠外与肠内营养, 2017, 24(6):351-354.
[9] 廖春华, 吴群强, 程建斌, 等 . 短肽型肠内营养制剂在重症患者营养治疗中的应用 . 贵州医药, 2019, 43(1):98-99.
[10] 赵 娜, 任古松, 张春霞 . 短肽型肠内营养制剂适用于老年脑卒中病人的营养支持 . 肠外与肠内营养, 2016, 23(1):34-36.
[11] 高薇薇, 阚建英, 于乃浩 . 幽门后喂养重症患者肠内营养制剂的选择 . 中华急诊医学杂志, 2020, 29(1): 87-91.
[12] Dhatariya K, Corsino L, Umpierrez GE. Management of Diabetes and Hyperglycemia in Hospitalized Patients. 2020-11-30[2021-09-07].https://www.ncbi.nlm.nih.gov/books/NBK279093/.
[13] McMahon MM, Nystrom E, Braunschweig C, et al. ASPEN Clinical Guidelines: Nutrition Support of Adult Patients With Hyperglycemia. JPEN J Parenter Enteral Nutr,2013,37(1):23-26.
[14] McClave SA, Taylor BE, Marlindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine(SCCM) and American Society for Parenteral and Enteral Nutrition(ASPEN). JPEN J Parenter Enteral Nutr, 2016, 40(2):159-211.
[15] Santacruz CA, Orbegozo D, Vincent JL, et al. Modulation of Dietary Lipid Composition During Acute Respiratory Distress Syndrome: Systematic Review and Meta Analysis. JPEN J Parenter Enteral Nutr, 2015,39(7): 837-8465.
[16] 国家医保局、人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录（2020 年）》的通知 . http://www.gov.cn/zhengce/zhengceku/2020-12/28/content_5574062.html

备注/Memo

备注/Memo:
作者简介 ：吴 迪，主管药师，药学本科，从事临床药学肠外肠内营养方向工作。E-mail：nanjingwudi@126.com 通讯作者 ：房文通，E-mail：fwtfu@163.com
更新日期/Last Update: 1900-01-01